Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AMDL has received FDA clearance to market the AMDL-ELISA DR-70 as a safe and effective blood test for monitoring patients who have been previously diagnosed with colorectal cancer.
Subscribe to our email newsletter
The FDA clearance to market was based upon data showing DR-70 (FDP) has the ability to monitor the progression of colorectal cancer post-surgery in patients who are biopsy confirmed with this disease.
Gary Dreher, CEO of AMDL, said: “This clearance to market provides CRC patients with access to a potentially lifesaving test. Post-surgery testing with DR-70 is a valuable aid in monitoring disease progression in patients previously diagnosed with colorectal cancer.”